Peanut Allergy Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Antihistamines, Epinephrine, Immunotherapies, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 616.29 Million
CAGR (2026-2031)	13.69%
Fastest Growing Segment	Antihistamines
Largest Market	North America
Market Size (2031)	USD 1330.82 Million

Market Overview

The Global Peanut Allergy Treatment Market will grow from USD 616.29 Million in 2025 to USD 1330.82 Million by 2031 at a 13.69% CAGR. The Global Peanut Allergy Treatment Market comprises pharmaceutical formulations and immunotherapies, such as oral and epicutaneous regimens, intended to induce desensitization to peanut allergens and mitigate the risk of severe anaphylactic reactions. The primary drivers of this market include the escalating global prevalence of IgE-mediated food allergies and substantial financial support for clinical development programs aimed at establishing long-term tolerance in pediatric and adult populations. This commitment to advancing therapeutic solutions is evident in recent industry funding; according to the National Peanut Board, in 2025, the organization announced a cumulative investment exceeding $38 million dedicated specifically to food allergy research and outreach initiatives.

One significant challenge potentially impeding market expansion is the risk of severe adverse events associated with current immunotherapy treatments, which necessitates strict Risk Evaluation and Mitigation Strategies. The potential for treatment-induced anaphylaxis requires continuous medical supervision during the initial dosing phases, thereby increasing the burden on healthcare infrastructure and limiting patient accessibility in resource-constrained settings.

Key Market Drivers

The Surge in Regulatory Approvals for Novel Therapeutics is fundamentally reshaping the Global Peanut Allergy Treatment Market by expanding patient eligibility and geographic reach. Regulatory bodies are increasingly validating oral and epicutaneous immunotherapies, facilitating market entry for formulations targeting younger demographics where early intervention is critical. This shift allows manufacturers to address the severe unmet need in pediatric populations previously limited to avoidance strategies. For instance, according to Stallergenes Greer, January 2025, in the 'European Commission approves the extension of the indication of Palforzia' press release, the company received marketing authorization for the treatment of toddlers aged 1 through 3 years with a confirmed diagnosis. Such approvals not only broaden the addressable market but also encourage further innovation in desensitization protocols across the industry.

Advancements in Oral and Epicutaneous Immunotherapy Modalities are driving commercial growth by offering more convenient and effective administration routes, such as needle-free epinephrine and precise oral dosing. These technological improvements significantly enhance patient compliance and safety, translating clinical efficacy into substantial revenue streams for key market players. According to ARS Pharmaceuticals, November 2025, in the 'ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results', the company reported net product revenue of $31.3 million from neffy sales in the U.S., highlighting the rapid adoption of novel delivery systems. This commercial momentum is underpinned by strong financial confidence; according to ARS Pharmaceuticals, in 2025, the organization reported a cash position of $288.2 million, ensuring sustained funding for commercial expansion and real-world evidence generation.

Download Free Sample Report

Key Market Challenges

The growth of the Global Peanut Allergy Treatment Market is significantly constrained by the safety risks inherent in current immunotherapy protocols, particularly the potential for treatment-induced anaphylaxis. These risks necessitate rigorous Risk Evaluation and Mitigation Strategies, requiring prolonged medical supervision during the initial dose-escalation phases. This requirement imposes a substantial logistical burden on healthcare providers, as clinics must dedicate specialized staff and facilities to monitor patients for severe reactions after administration. Consequently, this creates a bottleneck in patient throughput, limiting the number of individuals who can be treated simultaneously and restricting access primarily to well-resourced medical centers.

The frequency of these adverse events remains a critical concern for market adoption and scalability. According to the American Academy of Allergy, Asthma & Immunology, in 2025, clinical data indicated that approximately 6.7% of pediatric patients undergoing peanut oral immunotherapy required epinephrine administration to manage adverse reactions. Such statistics underscore the high resource intensity of these treatments. The operational complexity associated with managing these safety risks deters smaller clinical practices from adopting these therapies, thereby hampering the widespread commercial expansion of peanut allergy treatments in the broader market.

Key Market Trends

The Advancement of Non-Invasive Epicutaneous Immunotherapy Patches is characterized by heavy capital investment in late-stage clinical trials to validate safety profiles distinct from systemic oral formulations. Unlike approved oral regimens that require ingestion, these patches leverage the skin’s immune properties to induce tolerance, prompting developers to sustain high operational spending to finalize regulatory submissions. This intensive developmental phase is evident in the financial activities of leading patch developers; according to DBV Technologies, October 2025, in the 'DBV Technologies Reports Third Quarter 2025 Financial Results' press release, the company recorded a net loss of $102.1 million, reflecting the substantial resources allocated to advancing the Viaskin Peanut program through pivotal testing phases.

Simultaneously, the Progression of Sublingual Immunotherapy Pipeline Candidates is introducing novel mucosal delivery systems designed to integrate desensitization seamlessly into daily patient routines. Emerging biotech firms are prioritizing formulations like toothpaste-based immunotherapies that target the oral mucosa, aiming to improve treatment adherence and minimize the lifestyle disruptions often associated with strict dosing schedules. The potential for high patient compliance with these convenient modalities is supported by recent clinical data; according to Intrommune Therapeutics, May 2025, in the 'Intrommune Therapeutics Announces Independent Editorial Highlighting Breakthrough Safety Data for Novel Toothpaste Peanut Allergy Treatment' press release, participants in the Phase 1 OMEGA trial demonstrated robust engagement, adhering to the treatment protocol on 97% of study days.

Segmental Insights

Based on recent industry analysis, the Antihistamines segment is emerging as the fastest-growing category within the Global Peanut Allergy Treatment Market. This rapid expansion is primarily driven by the increasing diagnosis of mild-to-moderate allergic reactions, where oral antihistamines serve as the first-line option for symptomatic relief of pruritus and urticaria. Furthermore, the segment is experiencing a demand surge due to its widespread adoption as an adjunctive therapy to mitigate adverse effects associated with novel Oral Immunotherapy (OIT) regimens. As regulatory bodies like the FDA approve new desensitization protocols, the concurrent need for antihistamines to enhance patient tolerance and safety is accelerating their market uptake significantly.

Regional Insights

North America holds a dominant position in the global peanut allergy treatment market, primarily driven by the rising prevalence of peanut allergies and substantial investments in clinical research. The region benefits from a supportive regulatory environment, exemplified by the U.S. Food and Drug Administration (FDA) granting approval for specific oral immunotherapies. This regulatory backing accelerates the commercialization of novel treatments. Furthermore, the presence of major pharmaceutical companies and established healthcare reimbursement structures facilitates broader patient access to these therapies, securing the region's leadership in the global sector.

Recent Developments

• In February 2025, Stallergenes Greer announced the commercial launch of Palforzia for the treatment of peanut allergy in toddlers aged one to three years in the United States. This product expansion followed the approval by the U.S. Food and Drug Administration for this younger age group, extending the therapy's indication beyond the previously approved range of four to seventeen years. The launch provided a new early intervention option designed to desensitize young children to peanut protein and mitigate the severity of allergic reactions caused by accidental exposure. This move reinforced the company's portfolio in the food allergy market following its earlier acquisition of the product.
• In October 2024, DBV Technologies reported positive regulatory updates regarding its Viaskin Peanut patch program for the treatment of peanut allergy. The company announced that it had reached an alignment with the U.S. Food and Drug Administration on a pathway for accelerated approval for toddlers aged one to three years. Furthermore, the company confirmed the completion of patient enrollment for its VITESSE Phase 3 pivotal study, which evaluated the safety and efficacy of the modified patch in children aged four to seven. These developments represented a critical step forward in the company's efforts to bring its epicutaneous immunotherapy to younger patient populations.
• In February 2024, the U.S. Food and Drug Administration approved Xolair (omalizumab) for the reduction of allergic reactions, including anaphylaxis, in adult and pediatric patients aged one year and older with IgE-mediated food allergies. This regulatory decision established the drug as the first and only medicine approved to reduce allergic reactions to multiple foods, such as peanuts, milk, and eggs, following accidental exposure. The approval was based on positive data from a Phase III clinical trial, which demonstrated that a significantly higher proportion of treated patients could tolerate small amounts of peanut protein without experiencing moderate to severe allergic symptoms compared to the placebo group.
• In January 2024, Intrommune Therapeutics and Inimmune Corporation announced a strategic collaboration to advance a novel oral mucosal immunotherapy for the treatment of peanut allergy. This partnership aimed to combine Intrommune’s proprietary toothpaste-based delivery system, which targets immune cells in the mouth, with Inimmune’s distinct immunotherapeutic technology designed to facilitate rapid desensitization. The joint effort focused on developing a more convenient and effective therapeutic option to address the significant unmet need for patients suffering from food allergies. By leveraging their respective platforms, the companies sought to create a treatment that could potentially offer long-lasting relief from allergic reactions.

Key Market Players

• Vedanta Biosciences, Inc.
• Alladapt Immunotherapeutics, Inc.
• Regeneron Pharmaceuticals Inc.
• Aravax Pty Ltd
• Teva Pharmaceutical Industries Limited
• Prota Therapeutics Pty Ltd.
• Aimmune Therapeutics, Inc.
• DBV Technologies SA
• Sanofi SA
• Mylan N.V.

By Drug Class	By Route of Administration	By Distribution Channel	By Region
Antihistamines Epinephrine Immunotherapies Others	Oral Intravenous Others	Retail Pharmacies Hospital Pharmacies Online Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Peanut Allergy Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Peanut Allergy Treatment Market, By Drug Class:

• Antihistamines
• Epinephrine
• Immunotherapies
• Others

• Peanut Allergy Treatment Market, By Route of Administration:

• Oral
• Intravenous
• Others

• Peanut Allergy Treatment Market, By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

• Peanut Allergy Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE